

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 Jun 2026

Treatment effect of Rituximab in myasthenia gravis patients resistant to the standard treatment

Protocol summary

Study aim

In this study, the treatment effect of Rituximab in Iranian myasthenia gravis patients resistant to the standard treatment, will be assessed.

Design

This is a prospective, phase 2 clinical trial without parallel groups.

Settings and conduct

This study will conduct in Alzahra hospital of Esfahan. Doctor will visit the patients at the time of enrollment and 3, 6, 9, and 12 months later.

Participants/Inclusion and exclusion criteria

Inclusion criteria: The patient has myasthenia gravis disease (according to AB test, RNS test, Edrophonium test, and Chest MDCT for thymus evaluation); patient resist to standard treatment for myasthenia gravis (including corticosteroid and azathioprine); The patient doesn't have Eaton Lambert syndrome; The patient doesn't administrate unconventional medications (herbal, acupuncture, etc.); Desire of the patient to participate in this study and Signing Written Informed Consent. Exclusion Criteria: Side effects of the drug occur which necessitate the discontinuation of the drug (The most severe side effects include: lethal injection reactions, hypersensitivity reactions, pancytopenia, infection, and organ dysfunction).

Intervention groups

There will be one Intervention group in this study. All patients will be treated with rituximab. It will be given as one gram in the first week, one gram in the third week, and then one gram in the sixth month intravenously (in normal saline solution).

Main outcome variables

Clinical status of the patients; Amount of daily activities in myasthenia gravis patients; Quality of patient's life; Signs and symptoms of myasthenia gravis; and Post-intervention Status of the patients

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190324043105N2**

Registration date: **2020-06-23, 1399/04/03**

Registration timing: **retrospective**

Last update: **2020-06-23, 1399/04/03**

Update count: **0**

Registration date

2020-06-23, 1399/04/03

Registrant information

Name

Alireza Eishi Oskouei

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3668 3554

Email address

alireza.eishi@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-01-01, 1397/10/11

Expected recruitment end date

2020-01-01, 1398/10/11

Actual recruitment start date

2019-06-20, 1398/03/30

Actual recruitment end date

2020-06-01, 1399/03/12

Trial completion date

2020-07-21, 1399/04/31

Scientific title

Treatment effect of Rituximab in myasthenia gravis patients resistant to the standard treatment

Public title

Effect of Rituximab in treatment of myasthenia gravis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

The patient has myasthenia gravis disease (positive AB test for AChR and MUSK *, evidence of myasthenia gravis disease in RNS test, positive Edrophonium test in the patient, and Chest MDCT for thymus involvement). * in Double Seronegative patients, both of these antibodies are negative; Therefore, the other 3 criteria used for diagnosis. In the patients positive for Anti AchR or negative for both antibodies, these characteristics must present: resistance to corticosteroid therapy or is contraindication; resistance to azathioprine treatment or its side effects occur which necessitate the discontinuation of the drug. In the patients positive for Anti MUSK, resistance to corticosteroid therapy or is contraindication, must occur. The patient doesn't have Eaton Lambert syndrome. The patient doesn't administrate unconventional medications (herbal, acupuncture, and etc.). Desire of the patient to participate in this study and Signing Written Informed Consent.

Exclusion criteria:

Age

From **18 years** old to **75 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **10**

Actual sample size reached: **14**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Other

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethical Committee of Isfahan University of Medical Sciences

Street address

Isfahan University of Medical Sciences, Hezar Jarib Ave., Isfahan, Iran

City

Isfahan

Province

Isfahan

Postal code

81746 73461

Approval date

2019-06-16, 1398/03/26

Ethics committee reference number

IR.MUI.MED.REC.1398.145

Health conditions studied

1

Description of health condition studied

Myasthenia gravis

ICD-10 code

G70.0

ICD-10 code description

Myasthenia gravis

Primary outcomes

1

Description

Clinical status of the patients

Timepoint

At the time of enrolling the patient to study, and then every 3 months in the following period of 1 year

Method of measurement

MGFA Clinical Classification Scale

2

Description

amount of daily activities in myasthenia gravis patients

Timepoint

At the time of enrolling the patient to study, and then every 3 months in the following period of 1 year

Method of measurement

MG-ADL scale

3

Description

quality of patient's life

Timepoint

At the time of enrolling the patient to study, and then every 3 months in the following period of 1 year

Method of measurement

MGQOL15

4

Description

signs and symptoms of myasthenia gravis

Timepoint

At the time of enrolling the patient to study, and then every 3 months in the following period of 1 year

Method of measurement

MG Composite Scale

5

Description

Post-intervention Status of the patients

Timepoint

after 6 and 12 months after the beginning of study

Method of measurement

MGFA Post-intervention Status

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Rituximab; Patients will be treated with rituximab. It will be given as one gram in the first week, one gram in the third week, and then one gram in the sixth month intravenously (in normal saline solution).

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-Zahra University Hospital

Full name of responsible person

Mahshid Golagha

Street address

EMG Department, Alzahra University Hospital, Soffeh Blvd., Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

mahshidgolagha32@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Dr Shaghayegh Haghjoo

Street address

Isfahan University of Medical Science, Hezar Jarib Street, Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

shaghayegh.haghjoo@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Mahshid Golagha

Position

Medical Intern

Latest degree

Medical doctor

Other areas of specialty/work

Neuroscience

Street address

EMG Department, Alzahra University Hospital, Soffeh Blvd., Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

mahshidgolagha32@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Keivan Basiri

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Neurology

Street address

EMG Department, Alzahra University Hospital, Soffeh Blvd., Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

basiri.keivan@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Alireza Eishi Oskouei

Position

General Practitioner

Latest degree

Medical doctor

Other areas of specialty/work

Neuroscience

Street address

EMG Department, Alzahra University Hospital, Soffeh Blvd., Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

alireza.eishi@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

after finishing this trial, MGFA Clinical Classification Scale, MG-ADL scale, MG Composite Scale, MGQOL15, and MGFA Post-intervention Status scores of all patients will be shared with all researchers.

When the data will become available and for how long

starting 6 months after publication

To whom data/document is available

The data will be available only to people working in academic institutions.

Under which criteria data/document could be used

the deidentified individual participant data will be available only for research purposes.

From where data/document is obtainable

alireza.eishi@yahoo.com

What processes are involved for a request to access data/document

by sending his/her request to mentioned Email, within less than a month: alireza.eishi@yahoo.com

Comments